Fostamatinib + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
Trial Timeline
Mar 25, 2021 โ Sep 5, 2022
NCT ID
NCT04629703About Fostamatinib + Placebo
Fostamatinib + Placebo is a phase 3 stage product being developed by Rigel Pharmaceuticals for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04629703. Target conditions include Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04629703 | Phase 3 | Completed |
Competing Products
20 competing products in Covid19